June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Analysis of mitochondrial dysfunction in a human stem cell model of retinal ganglion cell neurodegeneration
Author Affiliations & Notes
  • Jason S. Meyer
    Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States
    Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Jason Meyer Wisconsin Alumni Research Foundation, Code P (Patent)
  • Footnotes
    Support  NIH Grant EY024984, NIH Grant EY033022, NIH Grant EY033269, BrightFocus Grant G2020369
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1343. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jason S. Meyer; Analysis of mitochondrial dysfunction in a human stem cell model of retinal ganglion cell neurodegeneration. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1343.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Retinal ganglion cells (RGCs) are the projection neurons of the retina that serve as the connection between the eye and the brain. In this role, they allow for the transmission of visual information, with damage to this pathway in injury or disease leading to vision loss or blindness. Human pluripotent stem cells (hPSCs) can serve as powerful in vitro models for the study of retinal development and disease, with previous studies demonstrating the ability to model several aspects of RGC neurodegeneration in vitro. However, these studies have not focused upon the role of mitochondria in these processes, nor how disease states may alter properties of mitochondria. Thus, to address these shortcomings and to better understand how mitochondria are adversely affected in RGC neurodegenerative disease states, we have developed novel models of hPSC-derived RGCs and assessed how disease states may result in the dysfunction of mitochondria. Moreover, we have also analyzed how relevant glial cells may also be subject to mitochondrial dysfunction and assessed how dysfunctional glial cells may further exacerbate RGC neurodegeneration in disease states. Taken together, the results of our studies reveal a profound dysfunction of mitochondria in disease states, and underscore the importance for future studies to more precisely elucidate the role of mitochondrial dysfunction in neurodegeneration.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×